BioLineRx Ltd. (BLRX)’s Financial Results Comparing With DiaMedica Therapeutics Inc. (NASDAQ:DMAC)

Both BioLineRx Ltd. (NASDAQ:BLRX) and DiaMedica Therapeutics Inc. (NASDAQ:DMAC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLineRx Ltd. N/A 0.00 22.92M -0.21 0.00
DiaMedica Therapeutics Inc. N/A 65.68 8.34M -0.74 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for BioLineRx Ltd. and DiaMedica Therapeutics Inc.


Table 2 provides BioLineRx Ltd. and DiaMedica Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
BioLineRx Ltd. 0.00% 0% 0%
DiaMedica Therapeutics Inc. 0.00% 0% 0%

Institutional & Insider Ownership

Institutional investors owned 27.13% of BioLineRx Ltd. shares and 13.72% of DiaMedica Therapeutics Inc. shares. 3.46% are BioLineRx Ltd.’s share owned by insiders. Insiders Competitively, owned 8.37% of DiaMedica Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioLineRx Ltd. -4.81% -12.66% -12.04% -48.78% -57.13% -18.13%
DiaMedica Therapeutics Inc. -6.42% -15% -7.27% -53.92% -65.77% 5.15%

For the past year BioLineRx Ltd. had bearish trend while DiaMedica Therapeutics Inc. had bullish trend.


On 3 of the 4 factors DiaMedica Therapeutics Inc. beats BioLineRx Ltd.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.